Previously published evidence suggests that AHR, which is loosely related to inflammation, may be more likely to show ICS dose-dependence than FEV1, PEF or symptoms [9,12,31,61] and a dose-dependent rate of reduction of eNO and asthma symptoms has been observed [7,16,17]. This evidence concerns the gene AHR and asthma.